IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide, with 20% to 40% of IgAN patients eventually progressing to end-stage renal disease. There is currently no specific drug for IgAN treatment, and its clinical treatment is based on renin-angiotensin aldosterone system inhibitors, with the addition of corticosteroid steroids and immunosuppressants if necessary. Research has confirmed that the alternative pathway for complement activation is the most common complement activation pathway in IgAN, and complement factor H and its related proteins are important regulatory proteins of the pathway. With the continuous deepening of research, more and more scholars have begun to pay attention to the role of complement H factor in the pathogenesis of IgAN. This article systematically reviewed the role of complement H factor and its related proteins in IgAN, providing reference for exploring biomarkers for IgAN diagnosis and prognosis, and developing targeted drugs such as complement inhibitors.